Scribe secures $129M in a rare gene editing IPO

Scribe Therapeutics priced an initial public offering on July 23, 2026, raising close to $129 million in the first IPO for a gene editing company in more than two years, BioPharma Dive reported. The startup sold 8.58 million shares at $15 apiece, topping projections set earlier in the week. Shares are set to begin trading Friday on the Nasdaq under the ticker symbol "SCTX." Biotech IPOs have been on an upswing in 2026, with 14 companies pricing new stock issuances so far this year, already surpassing last year's total. Prior to Scribe's offering, companies had been pulling in a median of over $300 million per offering in 2026, far higher than recent years. Scribe's IPO is much smaller by comparison, as the company is earlier in its development journey, having only recently brought its first medicine into human testing. Scribe is using an epigenetic approach that can silence gene expression without altering DNA, targeting more common cardiometabolic diseases. Its lead candidate, STX-1150, stops production of the PCSK9 protein to lower LDL-C cholesterol, with data from a first-in-human trial expected in the first half of 2027. Two preclinical treatments target the genes LPA and APOC3, with human trials hoped for in 2027 or 2028.